LYTGOBI ist der erste irreversibel bindende FGFR-Inhibitor in der Europäischen Union (European Union), der zur Behandlung von Patienten mit Cholangiokarzinom eingesetzt wird ZUG, Schweiz, 4. Juli 2023 /PRNewswire/ — Taiho Oncology Europe GmbH und Taiho Pharmaceutical Co. Ltd. gaben heute…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.